Metagenomi Therapeutics

MGXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$43.066 M

$1.14 +1.79%

Close of 22 Sept 2026

Revenue

$25.2M

#2925 by revenue

Earnings

-$87.9M

Loss-making

Shares outstanding

37,777,105

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#130Instil BioTIL$48.4M
#131ScilexSCLX$45.4M
#132Metagenomi TherapeuticsMGX$43.1M
#133ElutiaELUT$35.9M
#134Aligos TherapeuticsALGS$35.5M

What if Metagenomi Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$800,325.21

Per share 702,040× higher

Bitcoin $1.74T

$46,103.45

Per share 40,442× higher

Nvidia $5.52T

$146,008.20

Per share 128,077× higher

Or at a round number

$100.0M $200.0M $500.0M $1.00B

Where these numbers come from

Share counts and financials for Metagenomi Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.